Bluegreen Vacations Holding Corp.
Bluegreen Vacations Holding Corp. (NYSE: BVH), relating to its proposed sale to Hilton Grand Vacations Inc. Under the terms of the agreement, BVH shareholders will receive $75.00 in cash per share they own.
Bluegreen Vacations Holding Corp. (NYSE: BVH), relating to its proposed sale to Hilton Grand Vacations Inc. Under the terms of the agreement, BVH shareholders will receive $75.00 in cash per share they own.
Alteryx, Inc. (NYSE: AYX), relating to its proposed sale to Clearlake Capital Group, L.P. and Insight Partners. Under the terms of the agreement, AYX shareholders are expected to receive $48.25 in cash per share they own.
Daseke, Inc. (Nasdaq: DSKE), relating to its proposed sale to TFI International, Inc. Under the terms of the agreement, DSKE shareholders will receive $8.30 in cash per share they own.
Karuna Therapeutics, Inc. (Nasdaq: KRTX), relating to its proposed sale to Bristol Myers Squibb. Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.
Summit Materials, Inc. (NYSE: SUM), relating to its sale to Cementos Argos S.A. Under the terms of the agreement, Cementos will receive approximately $1.2 billion in cash and 54.7 million shares of SUM. Cementos will own approximately 31% of the combined company on a fully diluted basis.
PGT Innovations, Inc. (NYSE: PGTI), relating to its proposed sale to Masonite International Corp. Under the terms of the agreement, PGTI shareholders will receive $7.50 in common shares of Masonite and $33.50 in cash per share they own.
United States Steel Corp. (NYSE: X), relating to its proposed sale to Nippon Steel Corp. Under the terms of the agreement, X shareholders are expected to receive $55.00 in cash per share they own.
Gracell Biotechnologies Inc. (Nasdaq: GRCL), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, AstraZeneca will acquire GRCL for $2.00 per share in cash (equal to $10.00 per American Depositary Share of GRCL), plus a non-tradable CVR worth $0.30 per share in cash (equal to $1.50 per ADS of GRCL) payable … Read more
RayzeBio, Inc. (Nasdaq: RYZB), relating to its proposed sale to Bristol-Myers Squibb Co. Under the terms of the agreement, RYZB shareholders are expected to receive $62.50 in cash per share they own.
HollySys Automation Technologies Ltd. (Nasdaq: HOLI), relating to its proposed sale to Ascendant Capital Partners. Under the terms of the agreement, HOLI shareholders will receive $26.50 in cash per share they own.